Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf your skin has become unusually sensitive to touch since starting Mounjaro, you are not imagining it. This sensation — sometimes described as tenderness, hypersensitivity or a feeling that light contact is uncomfortable — has been reported by people on tirzepatide, and there are a few plausible explanations worth understanding. Mounjaro (tirzepatide) is a prescription-only medicine requiring clinical assessment before it can be supplied; a prescriber who knows your full health picture is always the right person to evaluate any new symptom you notice on treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When people notice their skin feels sore or hypersensitive to touch, the first instinct is often to assume allergy. That concern is understandable, but it misses the more common picture. A genuine allergic reaction to tirzepatide would typically involve hives, widespread rash, facial swelling, or difficulty breathing, signs that require immediate medical attention. Diffuse skin sensitivity without those features points elsewhere.
The more likely explanations involve the nervous system adapting to a medicine that slows gastric emptying and alters gut-hormone signalling across the whole body. GLP-1 and GIP receptors are found in tissues well beyond the gut, including peripheral nerves and skin. Some people notice heightened sensitivity (skin that feels tender to light pressure, fabric, or temperature) as these pathways adjust during the early weeks of treatment or after a dose increase. It is not an indication that something has gone wrong with the medicine itself.
What the NHS tirzepatide patient information describes as injection-site reactions (local redness, swelling, itching at the injection spot) is a separate and more straightforward phenomenon, the body responding to a subcutaneous needle at a fixed site. Rotating between the abdomen, thigh and upper arm, and warming the pen in your hand for a minute or two before injecting, both reduce localised skin irritation. Sensitivity that is more generalised (all over the body or away from any injection site) is a different report, and the rest of this page focuses on that.
Losing body fat changes how the skin sits and how sensory nerves are supported. This happens faster on tirzepatide than many people expect: tirzepatide's clinical trial programme reported average weight reductions of around 20% over 72 weeks, and for some people changes begin within the first few months. As the fat layer thins, nerves that were cushioned become closer to the surface, which can make the skin feel more reactive to pressure or touch than it used to. This is not dangerous, but it is genuinely uncomfortable for some people.
There is also a hydration and nutrition dimension worth knowing. Reduced appetite (one of tirzepatide's intended effects) can lead to lower fluid and protein intake if people are not deliberate about it. Mild dehydration can make the skin feel tighter and more sensitive. Inadequate protein affects skin integrity over time. If your skin sensitivity arrived alongside feeling generally less hungry and you have not adjusted what you eat to maintain protein and fluid intake, that connection is worth considering. The NHS healthy weight guidance covers hydration and nutrition basics; your prescriber or a dietitian can help you build a practical eating pattern around treatment.
A further possibility is sun sensitivity. Some people on GLP-1 medicines report that their skin reacts more readily to UV exposure, which may relate to changes in skin thickness or localised inflammation. We have a dedicated resource on Mounjaro and sun sensitivity if that aspect is what you noticed.
Most reports of general skin sensitivity on Mounjaro follow a predictable arc: noticeable in the first few weeks or after a dose step up, then gradually settling. If yours fits that pattern and is mild, monitoring it and mentioning it at your next clinical review is a reasonable approach.
Seek prompt medical attention (same day or via 999 if severe) for: a rapidly spreading rash, skin that is hot, blistered or breaking down, swelling of the face or throat, or sensitivity accompanied by breathing difficulty. These could indicate a serious allergic response and need assessment now, not later.
Contact your prescriber or GP (non-urgently, within a day or two) for: sensitivity that is getting progressively worse rather than settling, sensitivity that began or worsened after a dose increase and is significantly affecting daily life, or any new skin change that is difficult to explain. Your prescriber may recommend staying at the current dose longer before titrating up, or may want to rule out an unrelated cause.
You can also report any suspected side effect (including generalised skin sensitivity) through the MHRA's Yellow Card scheme. Mounjaro carries a Black Triangle (▼) status, meaning the MHRA is actively collecting post-marketing safety data; your report genuinely matters to that process.
If you have questions about how sensitivity relates to the rest of your Mounjaro treatment, or you want to understand whether the same changes occur all over the body, our page on whole-body skin sensitivity on Mounjaro goes deeper on that question.
For most people, yes. Skin sensitivity tends to ease as the body acclimates to tirzepatide, either during the starter phase or after a stable period at a new dose. The full picture of whether and how quickly this resolves is explored on a dedicated page about whether Mounjaro skin sensitivity goes away, but the short answer is that it usually does, particularly once the dose has been steady for four to six weeks.
In the meantime: loose, soft fabrics reduce friction against sensitised skin. Fragrance-free moisturisers help maintain the skin barrier. Staying well hydrated and keeping protein intake adequate addresses the nutritional dimension. Avoiding very hot showers (which can temporarily amplify nerve sensitivity at the skin surface) is a small practical step that some people find useful.
One thing worth knowing about the process at nume: every repeat order goes through clinical review before it is approved. If skin sensitivity has been an ongoing issue, the prescriber reviewing your repeat can factor that into the decision about timing and dose, it is not a bureaucratic hurdle, it is how adjustments actually happen. Your treatment, when approved, arrives the next working day via DPD in plain, unbranded packaging, with tracking on your phone. The pen itself is a pre-filled KwikPen; the guidance on caring for sensitive skin during Mounjaro treatment includes practical tips on handling the pen and rotating injection sites to minimise local reactions.
If you are new to treatment or still deciding whether Mounjaro is right for you, our overview of weight-loss treatment options and details on Mounjaro cost can help you see the full picture before you start. Check your eligibility by beginning a free consultation with our prescribers.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.